A Phase 3 interventional study of TAK-881 and Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US) in Primary Immunodeficiency Diseases (PID), sponsored by Takeda. Active, not recruiting at 25 sites in 7 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 9 in phase 3, and was the 19th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Takeda
Ages 6+
By country, each count listing its studies:
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 14 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 47 across the 18 interventional studies, 113 across the 4 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to learn if TAK-881 is safe and well tolerated during long-term use in adults and children with PIDD who are eligible and completed study TAK-881-3001 (NCT05755035).
The participants will receive the first dose of TAK-881 immunoglobulin (IgG) infusion at the same dosage as the last dose administered in study TAK-881-3001 (NCT05755035). After the first TAK-881 infusion in study TAK-881-3002, the dosing interval (can be adjusted by participant/caregiver) and/or the dose of TAK-881 can be adjusted by the study doctor to every 2, 3 or 4 weeks at scheduled site visits.
Participants will visit the clinic every 12 weeks until the End of Study (EOS) visit.
The study consists of two Epochs: Epoch 1 and Epoch 2. In Epoch 1 eligible participants will have the opportunity to receive TAK-881 for a minimum of 6 months. After 6 months in study TAK-881-3002, the results of the anti-rHuPH20 binding antibody assay from either study TAK-881-3001 (NCT05755035) or study TAK-881-3002 (Epoch 1) will be used to determine the next steps in the study:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who meet ALL of the following criteria are eligible for this study:
Exclusion Criteria
Participants with potential to become pregnant who meet any one of the following criteria:-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epoch 1: Participants who completed study TAK-881-3001 (NCT05755035) and met eligibility criteria will receive TAK-881 using Koru 24 G HlgH Flo subcutaneous (SC) safety needle set (investigational in the US) at the same dose and same treatment interval as at the last infusion in TAK-881-3001 (NCT05755035) at Week 1 and at Weeks 13 and Week 25 of study TAK-881-3002. Epoch 2: Participants with anti-rHuPH20 antibody titer \>=1:160 at any time point during Study TAK-881-3001 (NCT05755035) and/or Study TAK-881-3002 Epoch 1, will continue receiving TAK-881 every 12 weeks for up to Week 121. After the first TAK-881 infusion in study TAK-881-3002, the interval and/or the dose may be adjusted only at scheduled site visits at the investigator's discretion.
Biological: TAK-881 · Device: Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US)
Participants will receive SC infusion of TAK-881.
Also known as: Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20).
The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to Week 121
Number of Participants With Infusion Withdrawals, Interruptions, and Infusion Rate Reductions due to TAK-881-related TEAEs
Time frame: Up to Week 121
Annualized Rate of all Infections
Time frame: Up to Week 121
Annualized Rate of Acute Serious Bacterial Infections (ASBIs)
Time frame: Up to Week 121
Annualized Rate of Episodes of Fever
Time frame: Up to Week 121
Time to First ASBI
Time frame: Up to Week 121
Duration of Infections
Time frame: Up to Week 121
Number of Participants With Positive Binding Antibodies and Neutralizing Antibodies to rHuPH20
Time frame: Up to Week 121
Trough Level of Total IgG
Time frame: Up to Week 121
Doses of TAK-881
Time frame: Up to Week 121
Treatment Interval of TAK-881
Time frame: Up to Week 121
Number of Infusions Per Month With TAK-881
Time frame: Up to Week 121
Number of Infusions Sites (Needle Sticks) per Month With TAK-881
Time frame: Up to Week 121
Number of Infusions Sites (Needle Sticks) per infusion With TAK-881
Time frame: Up to Week 121
Duration of Infusions (minutes) With TAK-881
Time frame: Up to Week 121
Monthly Infusion Time (minutes/month) With TAK-881
Time frame: Up to Week 121
Maximum Tolerated Infusion Rate per Site (milliliter/hour/site) With TAK-881
Time frame: Up to Week 121
Infusion Volume per Site (milliliter/site) With TAK-881
Time frame: Up to Week 121
Number of Participants who have Infusions of TAK-881 at Physical Location
Physical location includes site/infusion center or home.
Time frame: Up to Week 121
Number of Participants, Caregiver, or Healthcare Professional (HCP) who have Administration of TAK-881
Time frame: Up to Week 121
Treatment Satisfaction Questionnaire for Medication (TSQM-9) Scores in Participants Aged >=16 Years
TSQM-9 is a 9-item, validated, self-administered instrument to assess participants satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The item scores of each of the 3 domains are summed and transformed to create a total score of 0 (extremely dissatisfied) to 100 (extremely satisfied). Higher score indicates greater satisfaction in that domain.
Time frame: From Week 13 up to Week 121
Health-Related Quality of Life (HRQoL): EuroQol 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Score in Participants Aged >=12 Years
The EQ-5D-5L is a validated, self-administered assessment of overall health designed by the EuroQol Group. The instrument consists of two components: the EQ-5D descriptive system and the standard vertical EQ visual analogue scale (EQ-VAS). The descriptive system consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has five response categories: no problems, slight problems, some or moderate problems, severe problems, or extreme problems. Participants will be asked to describe their health state that day by choosing one of 5 responses that reflect the levels of severity for each of the 5 dimensions. The EQ-VAS measures one's self-perceived health today on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health) on which participants have to indicate their current health. Higher score indicates best health status.
Time frame: From Baseline up to Week 121
Treatment Preference Measured by a Disease-specific Questionnaire for TAK-881 in Participants Aged >=12 Years
The disease-specific treatment preference questionnaire is a self-administered, non-validated scale to assess participant preference for various attributes of IgG therapy and accompanying devices, such as ease of use of administration of TAK-881 complexity of administration, and convenience. The questionnaire consists of two components. The first component asks participants to indicate the extent to which they like or dislike aspects of TAK-881, including treatment frequency, time, ease, convenience, and complexity. Each item has five response categories: like very much, like, no preference, dislike, and dislike very much. The second component is a single question asking whether they would choose to continue receiving treatment after the trial ends.
Time frame: At Weeks 25 and 73
Number of Days not Able to go to School, Work, Daycare, or to Perform Normal Daily Activities Due to Infections and/or their Treatment or Other Illnesses
Time frame: Up to Week 121
Number of Days on Antibiotics
Time frame: Up to Week 121
Number of Hospitalizations With Indications (Infection or other Illnesses)
Time frame: Up to Week 121
Number of Days of Hospitalization
Time frame: Up to Week 121
Number of Acute Physician Visits Due to Infection or Other Illnesses
Time frame: Up to Week 121
Infusion Preparation Time For TAK-881 by HCP
Time frame: Up to Week 121
Infusion Preparation Time For TAK-881 by Participants/Caregiver
Time frame: Up to Week 121
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Nov 2024 (actual). Primary completion is estimated for May 2028, 42 months after the start.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's planned 42 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Immunodeficiency Diseases →